Systemic inflammation is a determinant of outcomes of CD40 agonist–based therapy in pancreatic cancer patients
Sign Up to like & getrecommendations! Published in 2021 at "JCI Insight"
DOI: 10.1172/jci.insight.145389
Abstract: Agonistic anti-CD40 monoclonal antibody (mAb) therapy in combination with chemotherapy (chemoimmunotherapy) shows promise for the treatment of pancreatic ductal adenocarcinoma (PDA). To gain insight into immunological mechanisms of response and resistance to chemoimmunotherapy, we analyzed… read more here.
Keywords: inflammation; chemoimmunotherapy; patients systemic; therapy ... See more keywords